Search

A retrospective chart review was conducted on 78 adult patients who developed QTc prolongation while being treated with various medications for nausea and emesis or for other therapeutic indications. The medications involved in the cases included ondansetron, haloperidol, hydroxyzine, metoclopramide, olanzapine, citalopram, sertraline, trazodone, and mirtazapine. The patients experienced QTc prolongation after receiving combinations of these medications, and all six patients received oral olanzapine for nausea and emesis. The study did not provide specific details about dosages, treatment durations, or patient outcomes. [Extracted from the article]

A 69-year-old woman experienced syndrome of inappropriate antidiuretic hormone secretion (SIADH) while being treated with sertraline and citalopram for major depression. She presented with vomiting and seizures, and laboratory tests revealed hyponatremia. The SIADH was attributed to the medications, and they were discontinued. The woman made a full recovery and was discharged from the hospital. [Extracted from the article]

A 69-year-old woman experienced syndrome of inappropriate antidiuretic hormone secretion (SIADH) while being treated with sertraline and citalopram for major depression. She presented with vomiting and seizures, and laboratory tests revealed hyponatremia. The SIADH was attributed to the medications, and they were discontinued. The woman made a full recovery and was discharged from the hospital. [Extracted from the article]

A 68-year-old woman with treatment-resistant depression (TRD) did not respond well to buspirone, citalopram, and nabilone. She had been struggling with severe depression, anxiety, and suicidal thoughts for 15 years and had tried various treatments without success. After being referred to the hospital in December 2021, it was discovered that she was taking citalopram, buspirone, and nabilone, but her score on the Dutch-Modified (DM)-TRD indicated a lack of efficacy. She later received supportive psychotherapy and ketamine, which led to significant improvements in her symptoms. However, she ultimately withdrew her request for medical aid in dying (MAiD). [Extracted from the article]

This article from Reactions Weekly discusses two cases of drug-induced suicidality in patients receiving off-label treatment with paroxetine and citalopram. In one case, a 16-year-old boy experienced this side effect while being treated for obsessive-compulsive disorder (OCD) with paroxetine. The other case involved a 25-year-old man who developed drug-induced suicidality during antidepressant treatment with citalopram. The article does not provide specific details about the routes, dosages, or duration of treatment in these cases. [Extracted from the article]

A 73-year-old woman experienced muscle pain as a result of a drug-drug interaction between atorvastatin, a medication for high cholesterol, and citalopram, a medication for depression. The woman had been taking atorvastatin for years and later started citalopram for depressive disorder. However, after two weeks of taking citalopram, she developed severe muscle pain in her calves and had difficulty climbing stairs. The woman's atorvastatin dose was reduced, and her muscle pain eventually disappeared. It was determined that the muscle pain was caused by the interaction between atorvastatin and citalopram. [Extracted from the article]

Author InformationAn event is serious (based on the ICH definition) when the patient outcome is:• * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important eventA 67-year-old man developed type·II diabetes-mellitus (T2DM) during treatment with citalopram for depression, donepezil for dementia and risperidone for psychosis [routes not stated; not all dosage frequencies not stated]. [Extracted from the article]

In a study conducted from March 2011 to March 2012, adult patients with depression were described as developing sexual dysfunction while being treated with citalopram, paroxetine, or sertraline. The specific dosages, routes of administration, time to reaction onsets, and outcomes were not provided. The reported side effects included decreased desire, difficulty with orgasm, and decreased arousal. The study included a small number of patients, and further research is needed to fully understand the relationship between these medications and sexual dysfunction. [Extracted from the article]

Over the whole treatment period of 3 years, no side effects of the botulinum-toxin-A therapy were observed. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event In a case series, et al. 56-year-old man exhibited a lack of efficacy during treatment with zinc, mirtazapine and citalopram for post-herpetic neuralgia [PHN; I routes and dosages not stated i ]. Regardless of treatment, no positive effect on the pain intensity was noted (lack of efficacy). [Extracted from the article]

Thereafter, the urine drug screen and mass spectrometry test results were confirmed with blood testing and repeat urine testing 12 hours after admission. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 7-week-old male infant developed serotonin syndrome following intoxication with citalopram. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A woman approximately at age of 50s exhibited lack of efficacy during treatment with citalopram for depressive disorder. The woman was first admitted in 2002 with headache, widespread body pain, insomnia, loss of interest, dissatisfaction and unhappiness. Eventually on November 2017, she was admitted to psychiatric clinic and as her sertraline dose was last time raised 1 week ago, decision was taken to wait to note the clinical effect. [Extracted from the article]

Reference 1 Direct Healthcare Professional Communication (DHPC): Citalopram and Escitalopram - Risk of Dose-dependent QT interval Prolongation Internet Document: 14 Jul 2022. The risk of dose-dependent QT-interval prolongation with the use of citalopram or escitalopram was the subject of a direct healthcare professional communication (DHPC) piece published in the recent Newsletter from the Egyptian Pharmaceutical Vigilance Center (EPVC). [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose A 23-year-old man developed vasoplegic syndrome, cardiogenic shock, convulsion, acidaemia, wide complex tachydysrhythmias and cardiac arrest following bupropion and citalopram overdose [ I dosages, routes and time to reactions onsets not stated i ]. The man was brought to an emergency department after overdose of his prescription medications including bupropion and citalopram. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 73-year-old woman developed carcinoid heart disease (CHD) and unmasking of underlying carcinoid syndrome (CS) during treatment with citalopram for major depressive episode with psychosis. It was noted that octreotide can modify the 3D configuration of somatostatin receptors, which affects receptor regulation and density at the cell surface suggestive of development of octreotide resistance. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose A 4-week-old boy developed agitation, gastro-oesophageal reflux, jitteriness, opisthotonus, isolated systolic hypertension and sinus tachycardia secondary to citalopram intoxication following an unintentional overdose of citalopram due to incorrect drug administration by his mother [ I time to reaction onsets not stated i ]. He also had isolated systolic hypertension, an ECG showed sinus tachycardia with normal intervals, and his heart rate was normal. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose A 17-year-old girl developed serotonin syndrome following overdose of citalopram and lamotrigine for suicidal purpose. Her the signs and symptoms indicated serotonin toxicity (serotonin syndrome) and treatment with cyproheptadine was initiated. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose A 33-year-old man developed drowsiness, recurrent generalised tonic-clonic seizure, nonspecific ST-T changes, prolonged QT interval and decreased level of consciousness following the ingestion of citalopram at an overdose in a suicide attempt. The man's generalised tonic-clonic seizure was lasted for 2 minutes and resolved without treatment. Massive citalopram overdose associated with recurrent seizures and bilateral shoulder dislocations. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 45-year-old woman developed reversible cerebral vasoconstriction syndrome (RCVS) during treatment with citalopram for depression [ I route and duration of treatment to reaction onset not stated i ]. Subsequent head CT scan showed right parafalcine posterior parietal intracerebral haemorrhage with overlying convexal subarachnoid haemorrhage (SAH); CT angiogram revealed baseline smooth/segmental narrowing of the distal anterior cerebral artery, smooth narrowing of the basilar artery and segmental narrowing of the posterior cerebral artery (diffuse cerebral vasospasm). After 9 months, a repeat CT angiogram revealed complete resolution of cerebral vasospasm, confirming RCVS. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 52-year-old man developed a syndrome of inappropriate antidiuretic hormone secretion (SIADH) and hyponatraemia during treatment with citalopram, gabapentin and topiramate for depression and epilepsy. A syndrome of inappropriate antidiuretic hormone secretion (SIADH) was suspected to be the cause of hyponatraemia. His lab test was positive of calcium-sensing receptor-stimulating antibodies [ I not all outcomes stated i ]. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event An elderly woman [ I exact age not stated i ] developed acute glaucoma during treatment with citalopram [ I route, dosage, indication and duration of treatment to reaction onset not stated i ]. Also, her acetazolamide and pilocarpine therapies were discontinued. A diagnosis of acute glaucoma secondary to citalopram was made after review of her medications. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 73-year-old woman developed cerebral haemorrhage during treatment with citalopram and edoxaban for non-valvular atrial fibrillation (NVAF) [ I routes not stated i ]. A brain CT scan revealed haematoma of >18mm diameter in the right intra-parenchymal thalamus-capsular area without compression of the third ventricle and with peripheric oedematous halo. During follow-up examination after 3 weeks, brain CT scan revealed improvement of brain hematoma. [Extracted from the article]

An 81-year-old man experienced decreased strength, nausea and poor appetite (flu-like symptoms), erythema and burning on the scalp, retching, intermittent chills, syndrome of inappropriate antidiuretic hormone (SIADH), hyponatraemia and catatonia during treatment with imiquimod for actinic keratosis. On day 17, he presented to hospital due to ongoing scalp erythema, nausea, poor appetite and weakness. The nausea, poor appetite and weakness were though to be consistent with possible systemic flu-like side effects of imiquimod. [Extracted from the article]

In a report, two women in their 30s [ I exact ages at reactions onsets not stated i ] were described, who developed Meige syndrome, sexual dysfunction or fatigue during treatment with citalopram, fluoxetine, sertraline or vortioxetine [ I routes not stated; not all dosages stated i ] for major depression or generalised anxiety disorder [ I not all times to reactions onsets stated i ]. On day 10 of the vortioxetine therapy, she developed unilateral blepharospasm, and oropharyngeal spasm developed after 5 days. [Extracted from the article]

B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event * Drug overdose An investigation report received from the Healthcare Safety Investigation Branch, United Kingdom, a female patient [ I age not stated i ] was described, who became unresponsive and later died after taking an overdose of propranolol and citalopram [ I routes and dosages not stated i ]. The female patient, who had been diagnosed with anxiety at the age of 11 years, received propranolol for one year. [Extracted from the article]